Cellular Origins, a Cambridge-based leader in manufacturing automation, today announced the successful closing of a $40 million over-subscribed Series A financing round, a major step toward industrializing the production of cell therapies.

The round was led by Johnson & Johnson Innovation – JJDC, Inc., with participation from Highland Europe, BGF, NYBC Ventures, and TTP Group.

Cell therapies, widely regarded as one of the most transformative advances in modern medicine, continue to face a persistent challenge: scaling manufacturing efficiently and reliably. This bottleneck is particularly critical in longevity and healthspan-focused medicine, where cell-based interventions are increasingly explored to address age-related degeneration, immune decline, and other chronic conditions associated with aging populations.

Despite rapid clinical advances, production processes remain labor-intensive, fragmented, and difficult to replicate across facilities, limiting patient access to these therapies. Cellular Origins aims to address this challenge with a robotics-led approach that bridges the gap between clinical promise and commercial reality.

At the core of the company’s strategy is its proprietary Constellation platform, which leverages robotic automation to connect existing third-party operations already standard in cell therapy manufacturing. The platform integrates seamlessly into current workflows, enabling traditionally manual, skilled tasks—often conducted in sterile cleanrooms—to be automated and coordinated through mobile robotics and automated sterile welding. This approach ensures not only speed, but consistency, preserving biological performance while reducing operational risk and spatial constraints.

By automating and scaling production, Cellular Origins enables the reliable manufacture of hundreds of thousands of doses, a scale previously difficult to achieve without compromising quality or increasing costs.

“This fundraise is a pivotal milestone in our mission to industrialize cell therapy manufacturing,” said Edwin Stone, CEO of Cellular Origins. “The support from our investors is a strong endorsement of both our technology and the urgent need for scalable, automated solutions in this space. It reflects the progress we, alongside our partners and customers, have made toward making cell therapies accessible at scale.”